ImmuCell Corporation
ICCC
Rank in Stocks
#19996
ImmuCell Corporation functions as an animal health enterprise, specializing in... ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Share Price
$10.22
Last synced: 2026-11-09
Market Cap
$92.82M
Change (1 day)
4.29%
Change (1 year)
63.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ImmuCell Corporation (ICCC)
Category
Healthcare
Operating Margin for ImmuCell Corporation (ICCC)
Operating Margin as of November 2026 TTM: 12.60%
According to ImmuCell Corporation's latest financial reports, its current operating margin (TTM) is 12.60%. At the end of 2025 the company had an operating margin of 5.97%.
Operating Margin history for ImmuCell Corporation from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 12.60% | 111.06% |
| 2025 | 5.97% | -196.45% |
| 2024 | -6.19% | -81.19% |
| 2023 | -32.90% | 165.75% |
| 2022 | -12.38% | -1,023.88% |
| 2021 | 1.34% | -114.91% |
| 2020 | -8.99% | 29.35% |
| 2019 | -6.95% | -47.23% |
| 2018 | -13.17% | 465.24% |
| 2017 | -2.33% | -124.97% |
| 2016 | 9.33% | -55.04% |
| 2015 | 20.75% | -862.87% |
| 2014 | -2.72% | 724.24% |
| 2013 | -0.33% | -107.25% |
| 2012 | 4.55% | -136.75% |
| 2011 | -12.38% | -21.35% |
| 2010 | -15.74% | 34.64% |
| 2009 | -11.69% | -53.61% |
| 2008 | -25.20% | -275.37% |
| 2007 | 14.37% | -10.47% |
| 2006 | 16.05% | -14.72% |
| 2005 | 18.82% | 475.54% |
| 2004 | 3.27% | -125.59% |
| 2003 | -12.78% | -248.26% |
| 2002 | 8.62% | -14.23% |
| 2001 | 10.05% | 37.11% |
| 2000 | 7.33% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -96.94% |
US
|
|
| -149.01% | -111.83% |
US
|
|
| 25.57% | -97.97% |
AU
|
|
| 31.23% | -97.52% |
BE
|
|
| 29.35% | -97.67% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about ImmuCell Corporation's operating margin
What is ImmuCell Corporation's operating margin?
ImmuCell Corporation's operating margin is 12.60%, as of Nov 2026.
What was ImmuCell Corporation's operating margin in 2025?
In 2025, ImmuCell Corporation's operating margin was 5.97%, compared with -6.19% in 2024.
How has ImmuCell Corporation's operating margin changed since 2020?
From 2020 to 2025, ImmuCell Corporation's operating margin was highest in 2025 (5.97%) and lowest in 2023 (-32.90%).
How does ImmuCell Corporation's operating margin compare with similar companies?
ImmuCell Corporation's operating margin (12.60%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.